MedAdvisor Limited — Cyborg Score 5/10

Strategic Profile

MedAdvisor operates a SaaS model focused on health information services within the pharmacy ecosystem. Its dual-product strategy—MedAdvisor (vaccination and clinical workflow solution) and THRiV (omni-channel patient management platform)—enables scale across multiple markets while leveraging established pharmacy partnerships as distribution channels.

Cyborg Score Rationale

The company demonstrates solid revenue generation (AUD 122M annually) and market presence across four countries, but carries elevated valuation multiples with limited profitability (792K profit on 165M market cap) and tight liquidity metrics. Growth trajectory shows promise but execution risks remain.

Top Insights

• Pharmacy-centric positioning provides defensible moat through established practitioner relationships and regulatory integration
• Multi-jurisdictional footprint (AU, NZ, US, UK) provides geographic diversification but requires localized compliance expertise
• Revenue of AUD 122M with minimal profitability (792K) suggests business in investment phase with path to margin expansion unclear
• Market cap volatility (-31.75% 1-year decline) and tight balance sheet (0.71 current ratio) indicate investor sentiment risk and limited financial flexibility

Named Competitors

• Pharmacy Management Systems — Traditional pharmacy workflow software
• Digital Patient Engagement — Patient compliance and health tracking platforms

Recent Developments

• Health program deal extended (timing from recent announcements)
• Quarterly earnings announced with modest share price movements
• Guidance upgraded due to stronger-than-expected performance (recent announcements)

Open the full interactive MedAdvisor Limited report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.